Hedenus 2003.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 349, Hodgkin disease, Non‐Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia, Waldenstrom´s disease; concomitant treatment: chemotherapy
Interventions	drug = Darbepoetin alpha dose = 2.25 µg/kg sc weekly hb‐target = 13‐14 g/dL (women), 13‐15 g/dL (men) planned ESA duration = 12 weeks
Outcomes	Primary: Hb response; secondary: transfusion, Hb change, QoL, safety
Notes	study number = 63455
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	based on a schedule specified by Amgen before the start of the study
Allocation concealment?	Low risk	central randomization